OBJECTIVES: Tobacco-derived carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) activates β-adrenergic receptor (β-AR) signaling through Src/focal adhesion kinases (FAKs)/mitogen-activated protein kinase to modulate proliferation, migration, and survival. Apigenin (4', 5, 7-trihydroxyflavone) is reported to attenuate proliferation and migration of cancer cells. This study was designed to determine the effects of apigenin on NNK-induced procarcinogenesis using human pancreatic cancer cells BxPC-3 and MIA PaCa-2, which express β-AR. METHODS: Proliferation and migration were assessed by standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and scratch assays. β-AR, FAK/mitogen-activated protein kinase and extracellular signal-regulated kinase (ERK) expression and activation were assessed by Western blotting and real-time polymerase chain reaction. RESULTS: 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone caused a dose- and time-dependent increase in BxPC-3 and MIA PaCa-2 cell proliferation that was inhibited by propranolol or apigenin. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone also stimulated a time-dependent increase in FAK and ERK activation that was suppressed by propranolol or apigenin. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone-enhanced gap closure at 24 hours was prevented by either propranolol or apigenin. CONCLUSION: Apigenin suppressed the effects of NNK on pancreatic cancer cell proliferation and migration that are mediated through the β-AR and its downstream signals FAK and ERK activation. These findings suggest a therapeutic role for this natural phytochemical in attenuating the procarcinogenic effects of NNK on pancreatic cancer proliferation and migration.
OBJECTIVES:Tobacco-derived carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) activates β-adrenergic receptor (β-AR) signaling through Src/focal adhesion kinases (FAKs)/mitogen-activated protein kinase to modulate proliferation, migration, and survival. Apigenin (4', 5, 7-trihydroxyflavone) is reported to attenuate proliferation and migration of cancer cells. This study was designed to determine the effects of apigenin on NNK-induced procarcinogenesis using humanpancreatic cancer cells BxPC-3 and MIA PaCa-2, which express β-AR. METHODS: Proliferation and migration were assessed by standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and scratch assays. β-AR, FAK/mitogen-activated protein kinase and extracellular signal-regulated kinase (ERK) expression and activation were assessed by Western blotting and real-time polymerase chain reaction. RESULTS:4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone caused a dose- and time-dependent increase in BxPC-3 and MIA PaCa-2 cell proliferation that was inhibited by propranolol or apigenin. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone also stimulated a time-dependent increase in FAK and ERK activation that was suppressed by propranolol or apigenin. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone-enhanced gap closure at 24 hours was prevented by either propranolol or apigenin. CONCLUSION:Apigenin suppressed the effects of NNK on pancreatic cancer cell proliferation and migration that are mediated through the β-AR and its downstream signals FAK and ERK activation. These findings suggest a therapeutic role for this natural phytochemical in attenuating the procarcinogenic effects of NNK on pancreatic cancer proliferation and migration.
Authors: M P Lutz; I B Esser; B B Flossmann-Kast; R Vogelmann; H Lührs; H Friess; M W Büchler; G Adler Journal: Biochem Biophys Res Commun Date: 1998-02-13 Impact factor: 3.575
Authors: Nagathihalli S Nagaraj; J Joshua Smith; Frank Revetta; M Kay Washington; Nipun B Merchant Journal: Mol Cancer Ther Date: 2010-08-03 Impact factor: 6.261
Authors: S Caltagirone; C Rossi; A Poggi; F O Ranelletti; P G Natali; M Brunetti; F B Aiello; M Piantelli Journal: Int J Cancer Date: 2000-08-15 Impact factor: 7.396
Authors: Laleh G Melstrom; Mohammad R Salabat; Xian-Zhong Ding; Benjamin M Milam; Matthew Strouch; Jill C Pelling; David J Bentrem Journal: Pancreas Date: 2008-11 Impact factor: 3.327
Authors: David Bentrem; Jennifer E Fox; Sandra Timm Pearce; Hong Liu; Sam Pappas; David Kupfer; James W Zapf; V Craig Jordan Journal: Cancer Res Date: 2003-11-01 Impact factor: 12.701
Authors: Daria R Bulanova; Yevhen A Akimov; Anne Rokka; Teemu D Laajala; Tero Aittokallio; Petri Kouvonen; Teijo Pellinen; Sergey G Kuznetsov Journal: Cell Adh Migr Date: 2017-02-06 Impact factor: 3.405